The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future - Wikidata - awgldk - TriplyDB

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

http://www.wikidata.org/entity/Q35038852

about

Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors.Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.

P2860

Q36798069-A4871DBA-3B95-4E30-B8AD-DDB5B1557CD5 Q48346165-2D65E046-A271-444D-A7BF-935B16CC1F6C

P2860

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

http://www.wikidata.org/entity/Q35038852

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

@ast

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

@en

type

label

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

@ast

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

@en

prefLabel

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

@ast

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

@en

P1433

Q35038852-6F173781-A26A-452B-9A96-8E5211C2EAFC

P1476

Q35038852-7AE95665-8497-48A4-BC8A-1604464554F1

P2093

Q35038852-1CE20B37-B804-4A0D-AB82-0CE578A9406F

Q35038852-83C1C99B-1799-4BE9-897D-D77DED2E8790

P2860

Q35038852-05491722-B34D-419D-B240-8A406EDFE364

Q35038852-0EC026A8-6B19-4A61-9A63-F650E378EF79

Q35038852-0FCF2D86-8B53-4C1F-8353-519054B14E2D

Q35038852-10DF4F68-81B0-4EF3-968A-4662D4E341CB

Q35038852-17070FA0-ADE2-4407-95AA-C6DAA06C5688

Q35038852-1737E8B1-11DB-457E-8F32-B9A1A3A4918D

Q35038852-1A985155-0EA3-46C5-A3A9-29F1E7A12DDC

Q35038852-1CD9A0DE-D546-436B-879F-C31AB8BE64B2

Q35038852-1CE35EFA-8FF0-4781-9C6B-3B13C3959E83

Q35038852-22B5B513-0AF0-47D7-BD4C-58E31CC294A8

P304

Q35038852-F8CF587D-A6A6-433B-8B0E-16B573E5DF1C

P31

Q35038852-C94F7F8C-5622-4868-870F-43495BAFD16C

P356

Q35038852-DFB34AFB-805C-43AC-B1C6-FCF5299393B5

P478

Q35038852-95A1852F-BD1D-41CA-852B-B1E89A082531

P577

Q35038852-8BD128F1-0D09-49A2-9D5F-E8AEDE6DB661

P5875

Q35038852-C23D3CBA-E201-4680-82FB-CB531C093F23

P698

Q35038852-E3A64A44-E501-4007-BF48-A8D2FF6890E0

P932

Q35038852-3B9BDBFB-766E-4399-AEF1-8152AF862244

P356

P1433

Advances in Hematology

P1476

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

@en

P2093

C McNamara

http://www.w3.org/2001/XMLSchema#string

S E Richardson

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

Twenty years of MOPP therapy for Hodgkin's disease

Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review.

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

P304

865870

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/865870

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51233069

http://www.w3.org/2001/XMLSchema#string

P698

21687653

http://www.w3.org/2001/XMLSchema#string

P932

3112512

http://www.w3.org/2001/XMLSchema#string